IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

CPhI: Saltigo shuts US site, abandons plans to build potent API capacity

1:19 AM MDT | October 12, 2012 | Deepti Ramesh in Madrid

Saltigo (Langenfeld, Germany), a Lanxess subsidiary, says it has discontinued production at the company’s Redmond, WA, site and that it has abandoned a previously announced plan to produce potent active pharmaceutical ingredients (API) at that site. “We have decided to focus more on launched products or products in Phase 3 clinical trials and the Redmond site was involved in products required during phases 1 and 2. So we have decided not to continue our activities in the US,” Wolfgang Schmitz, CEO of Saltigo, told CW at the CPhI trade...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa